Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 5/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | SPR | P35270 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952388 | 0.88 | DDB1 (0.50) | DDB1CRBNGPR119 | |
| SCHEMBL30724065 | 0.87 | CYP11B2 (0.49) | CYP11B2ACACBDDB1CRBNHDAC2 | |
| SCHEMBL30768912 | 0.82 | CYP11B2 (0.46) | CYP11B2ACACBDDB1CRBNHDAC2 | |
| SCHEMBL31554616 | 0.82 | DDB1 (0.54) | CYP11B2ACACBDDB1CRBNHDAC2 | |
| SCHEMBL31583592 | 0.79 | DDB1 (0.41) | DDB1CRBNHDAC2USP30GPR119 | |
| SCHEMBL31306782 | 0.78 | CYP3A4 (0.48) | CYP11B2ACACBDDB1CRBNHDAC2 | |
| SCHEMBL30643667 | 0.78 | DDB1 (0.49) | DDB1CRBNGPR119 | |
| SCHEMBL38658093 | 0.77 | DDB1 (0.55) | CYP11B2ACACBDDB1CRBNHDAC2 | |
| SCHEMBL29264332 | 0.77 | DDB1 (0.51) | DDB1CRBNGPR119 | |
| SCHEMBL25824549 | 0.77 | DDB1 (0.48) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006781-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | CYP11B2 138/4885ACACB 1629/4885DDB1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.